This document summarizes a cost-utility analysis comparing the standard therapy of ribavirin and pegylated interferon to newer sofosbuvir-based therapies for the treatment of hepatitis C genotype 1 and 3 patients in Portugal. For genotype 1 patients, the incremental cost-effectiveness ratio of sofosbuvir-based therapy was calculated to be 38,455€ per quality-adjusted life year gained compared to standard therapy. For genotype 3 patients, the standard therapy of ribavirin and pegylated interferon was found to be more effective and less costly than sofosbuvir-based therapy.